Affiliation:
1. Key Laboratory for Quality Research and Evaluation of Chemical Drugs, National Institutes for Food and Drug Control, Beijing 100029, China
2. Department of Laboratory Medicine, Affiliated Qingyuan Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan 511518, China
Abstract
Dezocine, which is well-known as an analgesic, had about 45% share of the Chinese opioid analgesic market. Since drug products containing impurities could bring serious health consequences, it was important to control the generation of impurities and degradation products in the dezocine product. In this study, two kinds of photodegradation products (i.e., degradation product 1 and degradation product 2) in the dezocine injection were isolated using high-performance liquid chromatography. The possible structures of the photodegradation products were identified using both high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. In addition, the possible generation mechanism showed that degradation product 1 was the oxidation product of dezocine, and degradation product 2 was the coupled dimer of dezocine. Finally, we found that the degradation rate of dezocine increased with the increase in light intensity. Moreover, the degradation of dezocine easily occurred under ultraviolet light in comparison with visible light. A deeper insight into the generation of the photodegradation products in the dezocine injection would directly contribute to the safety of drug therapy based on the dezocine injection by minimizing the degradant/impurity-related adverse effects of drug preparations.
Funder
Guangdong Basic and Applied Basic Research Fund
Medical Science and Technology Foundation of Guangdong Province
Reference27 articles.
1. González-González, O., Ramirez, I.O., Ramirez, B.I., O’Connell, P., Ballesteros, M.P., Torrado, J.J., and Serrano, D.R. (2022). Drug Stability: ICH Versus Accelerated Predictive Stability Studies. Pharmaceutics, 14.
2. Non-mutagenic Impurities–Recent Industry Experience of Using Dose Durational Limits in Drug Development;Lortie;Regul. Toxicol. Pharm.,2024
3. Characterization of Degradation Products and Process-related Impurity of Sutezolid by Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry;Guo;J. Pharm. Biomed. Anal.,2019
4. ICH Topic Q3A (R2) Impurities in New Drug Substances (2024, June 19). International Conference on Harmonisation. 25 October 2006. Available online: https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf.
5. Control Strategy Expectations in Early Clinical Phase Synthetic Oncology Programs: Two Global Regulatory Case Studies;Roberts;Org. Process Res. Dev.,2020